aromasin
pfizer pfe pharmaceuticals israel ltd - exemestane - coated tablets - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
aromasin exemestane 25mg tablet blister pack
pfizer australia pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: silicon dioxide; crospovidone; hypromellose; magnesium carbonate hydrate; mannitol; microcrystalline cellulose; methyl hydroxybenzoate; macrogol 6000; polysorbate 80; polyvinyl alcohol; sodium starch glycollate; sucrose; titanium dioxide; cetyl esters wax; purified talc; carnauba wax; shellac; iron oxide black; magnesium stearate; purified water; sorbic acid; dimeticone 100; dimeticonol; benzoic acid - aromasin is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,aromasin is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.
aromasin 25 mg coated tablets
ltt pharma limited - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors - steroidal aromatase inhibitor; anti-neoplastic agent - it is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2 – 3 years of initial adjuvant tamoxifen therapy and for the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.
aromasin 25 mg coated tablets
pfizer healthcare ireland - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin 25 mg coated tablets
pco manufacturing ltd. - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin 25 mg coated tablets
imbat limited - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin 25 mg coated tablets
imed healthcare ltd. - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin- exemestane tablet
pharmacia & upjohn company llc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. aromasin is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, aromasin can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fetal toxicit
aromasin- exemestane tablet
physicians total care, inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. aromasin tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.
aroma tablet
major interest sdn bhd - cinnamomum zeylanicum; eugenia aromatica; piper nigrum; zingiber officinale/halia suti; langues galanga; honey, dried powder -